# Pulmonary thromboembolism in Glanzmann Thrombasthenia: a case report and systematic literature review

**Authors:** Tayebe Mohammad Alizade, Reihaneh Karimi, Hossein Kazemizadeh, Niloofar Khoshnam Rad

PMC · DOI: 10.1007/s00277-026-06732-8 · Annals of Hematology · 2026-01-27

## TL;DR

A rare case of pulmonary embolism in a patient with Glanzmann Thrombasthenia challenges the belief that such patients are protected from blood clots.

## Contribution

This case report presents a rare instance of provoked pulmonary embolism in a Glanzmann Thrombasthenia patient and discusses management challenges.

## Key findings

- A GT patient developed pulmonary embolism two months after surgery and hemostatic treatment.
- Apixaban was effective for treating the embolism but led to a bleeding complication after discontinuation.
- The case highlights the narrow therapeutic window for anticoagulation in GT patients.

## Abstract

Glanzmann Thrombasthenia (GT) is a congenital platelet disorder characterized by a life-long bleeding tendency, historically considered protective against thrombosis. This report describes a rare case of pulmonary embolism (PE) in a patient with GT, challenging this assumption and highlighting a critical management paradox. A 55-year-old woman with GT underwent elective cervical discectomy. Her perioperative hemostatic regimen included a single prophylactic dose of recombinant Factor VIIa (90 µg/kg), platelet transfusions (preoperative and daily for 3 days), and tranexamic acid. Two months postoperatively, she presented with hemoptysis. CT pulmonary angiography confirmed bilateral segmental and subsegmental PE with pulmonary infarctions. Anticoagulation with apixaban was initiated, leading to symptom resolution and thrombus regression. Therapy was discontinued after four months following a spontaneous hemarthrosis, which was managed successfully. Provoked PE can occur in GT patients following major surgery and hemostatic support. Apixaban was effective for short-term treatment, but the subsequent bleeding complication highlights the narrow therapeutic window and the need to limit anticoagulation duration in this population.

The online version contains supplementary material available at 10.1007/s00277-026-06732-8.

## Linked entities

- **Chemicals:** apixaban (PubChem CID 10182969), tranexamic acid (PubChem CID 5526)
- **Diseases:** Glanzmann Thrombasthenia (MONDO:0031332), pulmonary embolism (MONDO:0005279), hemarthrosis (MONDO:0004431)

## Full-text entities

- **Genes:** ITGB3 (integrin subunit beta 3) [NCBI Gene 3690] {aka BDPLT16, BDPLT2, BDPLT24, CD61, FMAIT1, GP3A}, ITGA2B (integrin subunit alpha 2b) [NCBI Gene 3674] {aka BDPLT16, BDPLT2, CD41, CD41B, FMAIT2, GP2B}, F10 (coagulation factor X) [NCBI Gene 2159] {aka FX, FXA}, F5 (coagulation factor V) [NCBI Gene 2153] {aka FVL, PCCF, RPRGL1, THPH2, fV}, F2 (coagulation factor II, thrombin) [NCBI Gene 2147] {aka PT, RPRGL2, THPH1}, JAK2 (Janus kinase 2) [NCBI Gene 3717] {aka JTK10}
- **Diseases:** Myeloproliferative Neoplasm (MESH:D009369), epistaxis (MESH:D004844), DVT (OMIM:612862), Deep Vein Thrombosis (MESH:D020246), PE (MESH:D011655), hypercoagulability (MESH:D019851), VTE (MESH:D054556), bleeding (MESH:D006470), sPAP (MESH:D000071079), Obesity (MESH:D009765), GT (MESH:D013915), Hypertension (MESH:D006973), cataract (MESH:D002386), thrombosis (MESH:D013927), infarction (MESH:D007238), aggregation (MESH:D020914), Hemoptysis (MESH:D006469), autosomal recessive platelet disorder (MESH:D001791), intra-articular hemorrhage (MESH:D057072), menorrhagia (MESH:D008595), pain (MESH:D010146), inflammation (MESH:D007249), hematoma (MESH:D006406), hemarthrosis (MESH:D006395), bruising (MESH:D003288), deficiency of platelet surface GPIIb (MESH:D010534), Atrial Fibrillation (MESH:D001281), hypothyroidism (MESH:D007037), pulmonary infarction (MESH:D054060), Trauma (MESH:D014947), joint swelling (MESH:D007592)
- **Chemicals:** CTPA (-), levothyroxine (MESH:D013974), AC (MESH:D000186), dabigatran (MESH:D000069604), epinephrine (MESH:D004837), Heparin (MESH:D006493), ADP (MESH:D000244), rivaroxaban (MESH:D000069552), Vitamin K (MESH:D014812), idarucizumab (MESH:C000594745), LA (MESH:D007811), tranexamic acid (MESH:D014148), Apixaban (MESH:C522181), ristocetin (MESH:D012310), LMWH (MESH:D006495)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** G1691A

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12847078/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12847078/full.md

---
Source: https://tomesphere.com/paper/PMC12847078